Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Fineline Cube Mar 11, 2026
Company Deals Drug

AstraZeneca Initiates CLARITY-Gastric 02 Phase III – Sonesitatug Vedotin Combo Triggers $45 Million Milestone from KYM Biosciences

Fineline Cube Mar 11, 2026
Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer

Fineline Cube Mar 11, 2026
Company Drug

Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia

Fineline Cube Mar 11, 2026
Policy / Regulatory

China’s NMPA Seeks Feedback on Drug Quality Management Provisions

Fineline Cube Dec 1, 2022

China’s National Medical Products Administration (NMPA) has released a draft proposal titled “Provisions on the...

Company Deals

Luye Pharma’s Shandong Boan Bio Files for Hong Kong IPO

Fineline Cube Dec 1, 2022

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd, has filed...

Company Deals

Luca Healthcare Partners with Cambridge Cognition to Launch Cognitive Tools in China

Fineline Cube Dec 1, 2022

China-based digital health solutions provider Luca Healthcare has announced a strategic partnership and license agreement...

Company Drug

Luye Pharma’s Biosimilar to Amgen’s Xgeva Launched in China

Fineline Cube Dec 1, 2022

China-based Luye Pharma Group (HKG: 2186) has announced the first prescription of its biosimilar version...

Company Medical Device

Assure Tech Wins Japanese PDMA Approval for Pen-Type COVID-19 Antigen Test

Fineline Cube Dec 1, 2022

China-based Assure Tech (Hangzhou) Co., Ltd (SHA: 688075) has announced receiving marketing approval from Japan’s...

Company Drug

Double-Crane Pharma Gains NMPA Approval for COVID-19 Drug CX2101A Clinical Trials

Fineline Cube Dec 1, 2022

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving clinical trial approval from...

Company Medical Device

Lepu Medical Wins NMPA Approval for Disposable Pressure Microcatheter

Fineline Cube Dec 1, 2022

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Policy / Regulatory

China’s NMPA Shifts to Electronic Drug Filings from January 2023

Fineline Cube Dec 1, 2022

China’s National Medical Products Administration (NMPA) has released a notification indicating the initiation of electronic...

Company Medical Device

Hainan Hospital Launches IBI’s Smartbone ORTHO for Bone Repair

Fineline Cube Dec 1, 2022

The clinical application of Smartbone ORTHO, a polyester collagen bone repair material introduced by Hainan...

Company Drug

CSL Vifor and Fresenius Kabi Win China Approval for Ferinject

Fineline Cube Dec 1, 2022

Swiss firm CSL Vifor and Germany’s Fresenius Kabi have announced the first regulatory approval in...

Company Deals

China’s Pharma Firms Collaborate on Generic Version of Sun Pharma’s Carbamazepine

Fineline Cube Dec 1, 2022

Several China-based pharmaceutical companies, including Shanghai Zhongxi Sunve Pharmaceutical Co. Ltd, Shanghai Anbison Lab Co.,...

Company Drug

Youcare’s YKYYO17 Aerosol Inhalation Agent Approved for COVID-19 Clinical Study

Fineline Cube Dec 1, 2022

China-based Youcare Pharmaceutical Group’s YKYYO17 aerosol inhalation agent, a broad-spectrum coronavirus membrane fusion inhibitor polypeptide...

Company Deals

Henan Celnovte Biotechnology Raises RMB 100M in New Financing Round

Fineline Cube Dec 1, 2022

China-based Henan Celnovte Biotechnology Co., Ltd, a tumor in vitro diagnostic reagents (IVDs) and instruments...

Company Drug

Clover Biopharmaceuticals’ SCB-2019 Vaccine Reduces Household Transmission of COVID-19

Fineline Cube Dec 1, 2022

China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced that Clinical Infectious Diseases has published...

Company Drug

Ascletis Pharma Completes Enrollment for ASC40 Phase II Acne Study

Fineline Cube Dec 1, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced the completion of enrollment of 180 patients in...

Company Drug

Ascletis Pharma’s COVID-19 Drug Candidate ASC11 Accepted for Review by NMPA

Fineline Cube Nov 30, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its Investigational New Drug (IND) filing...

Company Deals

Hangzhou Polymed Biopharmaceuticals Raises Funds for Clinical Pipeline

Fineline Cube Nov 30, 2022

China-based Hangzhou Polymed Biopharmaceuticals has reportedly completed a Pre-Series A+ financing round, raising an undisclosed...

Company Deals

Fosun Pharma Weighs Sale of India’s Gland Pharma Amid Market Interest

Fineline Cube Nov 30, 2022

Shanghai Fosun Pharmaceutical Group Co. (HKG: 2196, SHA: 600196) is reportedly considering the sale of...

Company Deals

Fosun Pharma’s Gland Pharma to Acquire French CDMO Cenexi for EUR 120 Million

Fineline Cube Nov 30, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) announced that its India-based subsidiary, Gland Pharma Ltd...

Company Drug

Luye Pharma Initiates Phase II Study for LY 03014 in China

Fineline Cube Nov 30, 2022

China-based Luye Pharma Group (HKG: 2186) has announced the first patient dosing in a Phase...

Posts pagination

1 … 560 561 562 … 633

Recent updates

  • Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029
  • J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer
  • Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia
  • Zelgen’s Zesuning Launches Nationwide – First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up
  • Fosun Pharma’s Tenapanor (Vteglea) Issues First China Prescription – NHE3 Inhibitor Targets Hyperphosphatemia in Dialysis Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Company Drug

J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer

Company Drug

Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia

Company Drug

Zelgen’s Zesuning Launches Nationwide – First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.